London Stock Exchange AGI - Irish  AGI - London 

The Group's principal activity is developing and commercialising differentiated drug products for gastrointestinal diseases and disorders. It develops a range of product candidates for the treatment of gastrointestinal (GI) diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The Group has a portfolio of product candidates derived from the Known Molecular Entity (KME) approach to drug re-profiling methodology used to identify existing therapeutic drugs. Product candidates are Rezular, Mecamylamine CR, Omeprazole, Arbaclofen and 4-ASA-Na.


Copyright  2008